# Detailed Search Strategy: Synbiotics and Postbiotics in Multidrug-Resistant Tuberculosis Treatment Outcomes

## Search Question
Do synbiotics or postbiotics improve treatment outcomes in multidrug-resistant tuberculosis beyond standard care?

## Research Question Components
- **Population:** Adult patients with confirmed MDR-TB
- **Intervention:** Synbiotics or postbiotics as adjunct to standard MDR-TB treatment
- **Comparator:** Standard MDR-TB treatment alone
- **Outcome:** Treatment success, culture conversion, adverse events, mortality
- **Study Design:** RCTs, NRCTs, prospective cohorts, registry studies

## Search Strategy Development

### Step 1: Concept Identification
1. **Disease Terms:** multidrug-resistant tuberculosis, MDR tuberculosis, extensively drug-resistant tuberculosis, XDR-TB
2. **Intervention Terms:** synbiotic*, postbiotic*, probiotic*, prebiotic*, microbiome modulation, gut microbiota
3. **Treatment Terms:** treatment outcome*, cure rate*, conversion time*, sputum conversion
4. **Comparative Terms:** versus, compared, adjunct, add-on, additional therapy
5. **Study Design:** randomized controlled trial, clinical trial, cohort study, prospective study

### Step 2: Expanding Search Terms

#### Disease-Specific Terms
- multidrug-resistant tuberculosis, MDR-TB, extensively drug-resistant tuberculosis, XDR-TB
- tuberculosis resistant to rifampicin and isoniazid
- pre-extensively drug-resistant tuberculosis

#### Intervention Terms
- synbiotic*, synbiotics (combination probiotics and prebiotics)
- postbiotic*, postbiotics (fermentation metabolites, bacteriocins, short-chain fatty acids)
- probiotic*, probiotics (Lactobacillus, Bifidobacterium, Saccharomyces)
- prebiotic*, prebiotics (inulin, fructooligosaccharides, resistant starches)
- microbiome, microbiota, gut flora, commensal bacteria

#### Outcome Terms
- treatment outcome*, treatment success*, cure rate*
- sputum conversion, culture conversion, time to conversion
- treatment completion, treatment failure
- adverse event*, side effect*, toxicity, hepatotoxicity
- mortality, survival, all-cause death
- quality of life, QoL measures

## Database-Specific Search Strategies

### PubMed/MEDLINE Strategy

```
#1: (multidrug-resistant tuberculosis OR MDR tuberculosis OR extensively drug-resistant tuberculosis OR MDR-TB OR XDR-TB)[Title/Abstract]
#2: (synbiotic* OR postbiotic* OR probiotic* OR prebiotic* OR microbiome OR microbiota)[Title/Abstract]
#3: (treatment outcome* OR cure rate* OR conversion OR sputum conversion OR culture conversion OR efficacy)[Title/Abstract]
#4: (versus OR compared OR adjunct OR add-on OR additional OR standard care)[Title/Abstract]
#5: (randomized controlled trial OR clinical trial OR cohort study OR prospective study)[Publication Type]
#6: #1 AND #2 AND #3 AND (#4 OR #5 OR systematic review OR meta analysis)
```

**Complete PubMed Query:**
```
(multidrug-resistant tuberculosis[Title/Abstract] OR MDR tuberculosis[Title/Abstract] OR extensively drug-resistant tuberculosis[Title/Abstract] OR MDR-TB[Title/Abstract] OR XDR-TB[Title/Abstract]) AND (synbiotic*[Title/Abstract] OR postbiotic*[Title/Abstract] OR probiotic*[Title/Abstract] OR prebiotic*[Title/Abstract] OR microbiome[Title/Abstract] OR microbiota[Title/Abstract]) AND (treatment outcome*[Title/Abstract] OR cure rate*[Title/Abstract] OR conversion[Title/Abstract] OR sputum conversion[Title/Abstract] OR culture conversion[Title/Abstract] OR efficacy[Title/Abstract]) AND (versus[Title/Abstract] OR compared[Title/Abstract] OR adjunct[Title/Abstract] OR add-on[Title/Abstract] OR additional[Title/Abstract] OR standard care[Title/Abstract] OR randomized controlled trial[Publication Type] OR clinical trial[Publication Type])
```

### EMBASE Strategy
Incorporating broader European terminology and TB-specific indexing.

```
#1: multidrug-resistant tuberculosis/de OR extensively drug-resistant tuberculosis/de OR resistant tuberculosis/de
#2: synbiotic/ti,ab OR postbiotic/ti,ab OR probiotic/ti,ab OR prebiotic/ti,ab OR microbiome/ti,ab OR microbiota/ti,ab
#3: treatment outcome/de OR cure rate/ti,ab OR conversion/ti,ab OR sputum culture conversion/ti,ab OR efficacy/ti,ab
#4: versus/ti,ab OR compared/ti,ab OR adjunct/ti,ab OR add-on/ti,ab OR additional therapy/ti,ab
#5: randomized controlled trial/de OR clinical trial/de OR cohort analysis/de OR prospective study/de
#6: #1 AND #2 AND #3 AND (#4 OR #5 OR systematic review/de)
```

### Cochrane Central Register of Controlled Trials (CENTRAL)

```
#1: MeSH descriptor: [Tuberculosis, Multidrug-Resistant] explode all
#2: (synbiotic* or postbiotic* or probiotic* or prebiotic* or microbiome or microbiota):ti,ab,kw
#3: MeSH descriptor: [Treatment Outcome] or (treatment outcome* or cure rate* or conversion* or efficacy):ti,ab,kw
#4: (versus or compared or adjunct or add-on or additional):ti,ab,kw
#5: #1 and #2 and #3 and #4
```

### Web of Science Core Collection

```
TOPIC: ((multidrug-resistant tuberculosis OR MDR tuberculosis OR extensively drug-resistant tuberculosis OR MDR-TB OR XDR-TB) AND (synbiotic* OR postbiotic* OR probiotic* OR prebiotic* OR microbiome OR microbiota) AND (treatment outcome* OR cure rate* OR conversion* OR sputum conversion OR culture conversion OR efficacy) AND (versus OR compared OR adjunct OR add-on OR additional OR standard care))

REFINED BY: DOCUMENT TYPES: (ARTICLE OR REVIEW OR CLINICAL TRIAL)
```

### ClinicalTrials.gov Search Strategy

Advanced Search Filters:
- Condition/Disease: Multidrug-Resistant Tuberculosis OR MDR Tuberculosis OR Extensively Drug-Resistant Tuberculosis
- Interventions: probiotic OR synbiotic OR postbiotic OR prebiotic OR microbiome
- Study Type: Interventional Studies
- Phase: Any Phase
- Status: Completed OR Recruiting OR Active OR Terminated OR Unknown
- Additional filters: Has Results Available (when applicable)

**Text Search:**
```
(multidrug-resistant tuberculosis OR MDR TB OR extensively drug-resistant) AND (synbiotic OR postbiotic OR probiotic OR prebiotic OR microbiome OR microbiota) AND (treatment OR outcome OR cure OR conversion OR efficacy OR randomized trial OR clinical trial)
```

## Regional Database Searches

### WHO ICTRP (International Clinical Trials Registry Platform)
Using advanced search filters for global TB study registries.

### LILACS (Latin American and Caribbean Health Sciences)
```
((tuberculosis resistente a múltiples medicamentos OR tuberculosis multirresistente) AND (sinbióticos OR posbióticos OR probióticos OR prebióticos OR microbioma)) AND (tratamiento OR curación OR conversión OR resultado)
```

### African Journals Online
Focused search for studies from high TB burden African countries.

### ProQuest Dissertations & Theses Global
```
(multidrug-resistant tuberculosis OR MDR tuberculosis) AND (synbiotic* OR postbiotic* OR probiotic* OR microbiome) AND treatment outcome*
```

## Additional Search Methods

### Grey Literature Sources

#### WHO Publications
- WHO consolidated guidelines for drug-resistant TB
- WHO technical briefs on innovative TB treatments
- WHO global tuberculosis reports
- WHO Stop TB Partnership publications

#### Conference Proceedings
- Union World Conference on Lung Health abstracts
- European Respiratory Society Congress abstracts
- American Thoracic Society International Conference abstracts

### Reference List Scanning

Reference lists of all included studies and relevant systematic reviews will be manually searched for additional eligible studies.

### Expert Consultation

TB and microbiome experts will be contacted for knowledge of ongoing or unpublished studies:
- Prof. Giovanni Battista Migliori (European Respiratory Society)
- Prof. Keertan Dheda (University of Cape Town Lung Institute)
- WHO Global TB Programme technical officers
- International Union Against Tuberculosis and Lung Disease (The Union) members

### Update Search Strategy

Monthly update searches will be conducted until manuscript submission using PubMed automatic alerts and ClinicalTrials.gov saved searches.

## Search Strategy Quality Control

### Pre-Search Validation
- Pilot searches conducted in August-September 2025
- Strategy calibrated against known studies:
  - Zhou Y et al. Front Pharmacol 2021 (Lactobacillus probiotics in TB)
  - Wang J et al. Int J Tuberc Lung Dis 2019 (Gut microbiota in TB patients)
  - Pilot studies in MDR-TB with microbiome interventions

### Sensitivity and Precision Metrics
- **PubMed Strategy:** Target sensitivity 95%, precision estimation 85%
- **EMBASE Strategy:** Target sensitivity 97%, precision estimation 80%
- **Cochrane CENTRAL:** Target sensitivity 93%, precision estimation 90%

## Inclusion/Exclusion Filters

### Time Filters
- Publication date: 2010 - September 2025 (gut microbiota research emergence)
- No restrictions on study initiation dates

### Geographic Scope
- No geographic restrictions (global MDR-TB burden assessment)
- High-burden countries prioritized (India, China, Russia, South Africa, etc.)

### Language Restrictions
- Primary search: English language publications
- Secondary screening: Abstracts in major languages (Chinese, Russian, Spanish, French)
- Full-text translation: Professional translation services for methodologically critical studies

## Search Documentation

All searches will be documented with:
- Complete search strings with date/time stamps
- Raw result counts per database
- Deduplication process and final unique records
- PRISMA flow diagram tracking
- Quality control checklists for search execution

This comprehensive search strategy ensures systematic identification of all available evidence on synbiotics and postbiotics in MDR-TB treatment for evidence synthesis and clinical guidance.
